• Explore /
  • Poster
  • / Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.

Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.

Abstract Poster

Authors

null

Masatoshi Kudo

Kindai University Faculty of Medicine, Osaka-Sayama, Japan

Masatoshi Kudo , Ana Matilla , Armando Santoro , Ignacio Melero , Antonio Cubillo Gracian , Mirelis Acosta-Rivera , Su Pin Choo , Anthony B. El-Khoueiry , Ryoko Kuromatsu , Bassel F. El-Rayes , Kazushi Numata , Yoshito Itoh , Francesco Di Costanzo , Oxana V. Crysler , Maria Reig , Yun Shen , Jaclyn Neely , Carlos Baccan , Bruno Sangro , Christine Marie Dela Cruz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01658878

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 327)

DOI

10.1200/JCO.2019.37.4_suppl.327

Abstract #

327

Poster Bd #

H5

Abstract Disclosures

Similar Posters

Poster

2017 Gastrointestinal Cancers Symposium

Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.

Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study.

First Author: Ignacio Melero

First Author: Todd S. Crocenzi

First Author: Aiwu Ruth He

First Author: Bruno Sangro